Biocon Ltd is quoting at Rs 332.25, down 1.35% on the day as on 13:19 IST on the NSE. The stock jumped 21.26% in last one year as compared to a 3.77% rally in NIFTY and a 9.52% spurt in the Nifty ...

Biologics Ltd (BBL), a subsidiary of Biocon Limited, has secured a major regulatory milestone with the European Commission ...

Shaw, Founder and Executive Chairperson of Biocon, on catching up with China, the right recruitment policies, and more.

The Commission held that OCDs bought by Goldman in Biocon Biologics, translating to a 3.8% stake, were not a passive ...

Biocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This ...

Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...